Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma

Avi Eisenthal, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

We have cross-linked, using succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) as a heterobifunctional reagent, anti-B16 melanoma monoclonal antibody to lymphokine activated killer (LAK) cells, independent of the Fc receptor. The conditions of such linkage were optimized so that the cytotoxic properties of LAK cells, as measured in a 4 h chromium release assay against fresh tumor cells, were preserved. Using the techniques described here, covalent cross linking of anti-B16 antibody to LAK cells preserved the reactivity of this antibody to antigens on B16 melanoma cells, and preserved the cytotoxic properties of the antibody-bound LAK cells to lyse B16 tumor cells and other tumor cells in vitro. Cross-linking antibody remained active on the surface of LAK cells for as long as 24h after the completion of binding. Treatment of established B16 melanoma pulmonary or subcutaneous (s.c.) tumors with LAK cells cross-linked to anti-B16 melanoma monoclonal antibody did not significantly alter their therapeutic efficacy over untreated cells. The possible explanations for these in vivo observations and suggested approaches to increase the efficacy of the cross-linked LAK cells are discussed.

Original languageEnglish (US)
Pages (from-to)387-400
Number of pages14
JournalClinical and Experimental Metastasis
Volume6
Issue number5
DOIs
StatePublished - Sep 1988
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Experimental Melanomas
Monoclonal Antibodies
Therapeutics
Antibodies
Neoplasms
Fc Receptors
Chromium
Anti-Idiotypic Antibodies
Antigens
Lung

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells : possible role in the therapy of B16 melanoma. / Eisenthal, Avi; Rosenberg, Steven A.

In: Clinical and Experimental Metastasis, Vol. 6, No. 5, 09.1988, p. 387-400.

Research output: Contribution to journalArticle

@article{4456966f3bd5445fb3654fe4cbce60cc,
title = "Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma",
abstract = "We have cross-linked, using succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) as a heterobifunctional reagent, anti-B16 melanoma monoclonal antibody to lymphokine activated killer (LAK) cells, independent of the Fc receptor. The conditions of such linkage were optimized so that the cytotoxic properties of LAK cells, as measured in a 4 h chromium release assay against fresh tumor cells, were preserved. Using the techniques described here, covalent cross linking of anti-B16 antibody to LAK cells preserved the reactivity of this antibody to antigens on B16 melanoma cells, and preserved the cytotoxic properties of the antibody-bound LAK cells to lyse B16 tumor cells and other tumor cells in vitro. Cross-linking antibody remained active on the surface of LAK cells for as long as 24h after the completion of binding. Treatment of established B16 melanoma pulmonary or subcutaneous (s.c.) tumors with LAK cells cross-linked to anti-B16 melanoma monoclonal antibody did not significantly alter their therapeutic efficacy over untreated cells. The possible explanations for these in vivo observations and suggested approaches to increase the efficacy of the cross-linked LAK cells are discussed.",
author = "Avi Eisenthal and Rosenberg, {Steven A.}",
year = "1988",
month = "9",
doi = "10.1007/BF01760574",
language = "English (US)",
volume = "6",
pages = "387--400",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells

T2 - possible role in the therapy of B16 melanoma

AU - Eisenthal, Avi

AU - Rosenberg, Steven A.

PY - 1988/9

Y1 - 1988/9

N2 - We have cross-linked, using succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) as a heterobifunctional reagent, anti-B16 melanoma monoclonal antibody to lymphokine activated killer (LAK) cells, independent of the Fc receptor. The conditions of such linkage were optimized so that the cytotoxic properties of LAK cells, as measured in a 4 h chromium release assay against fresh tumor cells, were preserved. Using the techniques described here, covalent cross linking of anti-B16 antibody to LAK cells preserved the reactivity of this antibody to antigens on B16 melanoma cells, and preserved the cytotoxic properties of the antibody-bound LAK cells to lyse B16 tumor cells and other tumor cells in vitro. Cross-linking antibody remained active on the surface of LAK cells for as long as 24h after the completion of binding. Treatment of established B16 melanoma pulmonary or subcutaneous (s.c.) tumors with LAK cells cross-linked to anti-B16 melanoma monoclonal antibody did not significantly alter their therapeutic efficacy over untreated cells. The possible explanations for these in vivo observations and suggested approaches to increase the efficacy of the cross-linked LAK cells are discussed.

AB - We have cross-linked, using succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) as a heterobifunctional reagent, anti-B16 melanoma monoclonal antibody to lymphokine activated killer (LAK) cells, independent of the Fc receptor. The conditions of such linkage were optimized so that the cytotoxic properties of LAK cells, as measured in a 4 h chromium release assay against fresh tumor cells, were preserved. Using the techniques described here, covalent cross linking of anti-B16 antibody to LAK cells preserved the reactivity of this antibody to antigens on B16 melanoma cells, and preserved the cytotoxic properties of the antibody-bound LAK cells to lyse B16 tumor cells and other tumor cells in vitro. Cross-linking antibody remained active on the surface of LAK cells for as long as 24h after the completion of binding. Treatment of established B16 melanoma pulmonary or subcutaneous (s.c.) tumors with LAK cells cross-linked to anti-B16 melanoma monoclonal antibody did not significantly alter their therapeutic efficacy over untreated cells. The possible explanations for these in vivo observations and suggested approaches to increase the efficacy of the cross-linked LAK cells are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0023683848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023683848&partnerID=8YFLogxK

U2 - 10.1007/BF01760574

DO - 10.1007/BF01760574

M3 - Article

C2 - 3378376

AN - SCOPUS:0023683848

VL - 6

SP - 387

EP - 400

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 5

ER -